Document:

Exhibit
10.1 

 

Royalty Interest Purchase Agreement

 

This
Royalty Interest Purchase Agreement (this “Agreement”), dated as of August 24, 2022, is entered into by and
between Jaguar Health, Inc., a Delaware corporation (“Company”), and
Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns
(“Investor”).

 

A.       Company
and Investor are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the Securities
Act of 1933, as amended (the “1933 Act”), and the rules and regulations promulgated thereunder by the United States
Securities and Exchange Commission (the “SEC”).

 

B.       Investor
desires to purchase and Company desires to issue and sell, upon the terms and conditions set forth in this Agreement, a royalty interest
in the form attached hereto as Exhibit A (the “Interest”), upon the terms and subject to the limitations and
conditions set forth in such Interest.

 

C.       This
Agreement, the Interest, and all other certificates, documents, agreements, resolutions and instruments executed and delivered to any
party under or in connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as
the “Transaction Documents”.

 

NOW, THEREFORE, in
consideration of the above recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
Company and Investor hereby agree as follows:

 

1.                  
Purchase and Sale of Interest.

 

1.1.              Purchase of Interest. Company shall issue and sell to Investor and Investor agrees to purchase from Company the Interest.
In consideration thereof, Investor shall pay $4,000,000.00 (the “Purchase Price”) to Company at the Closing (as defined
below).

 

1.2.              Form of Payment. On the Closing Date (as defined below), Investor shall pay the Purchase Price to Company via wire transfer
of immediately available funds against delivery of the Interest.

 

1.3.             
Closing Date. The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur
on August 24, 2022 so long as all of the conditions set forth in Section 5 and Section 6 below have been satisfied, or such other mutually
agreed upon date (the date upon which the Closing actually occurs, the “Closing Date”). The Closing shall occur on
the Closing Date by means of the exchange by email of signed .pdf documents, but shall be deemed for all purposes to have occurred at
the offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.

 

1.4.              Transaction Expense Amount. Company agrees to pay $25,000.00 to Investor to cover Investor’s legal fees, accounting
costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of the Interest, which
amount will be deducted from the Purchase Price at Closing.

 

    1 

     

    

 

2.                   Investor’s
Representations and Warranties. Investor represents and warrants to Company that as of the Closing Date: (i) this Agreement has
been duly and validly authorized; (ii) Investor has all necessary power and authority under all applicable provisions of law to
execute and deliver each Transaction Document and to carry out their provisions; (iii) this Agreement constitutes a valid and
binding agreement of Investor enforceable in accordance with its terms; (iv) Investor is an “accredited investor” as
that term is defined in Rule 501(a) of Regulation D of the 1933 Act; (v) Investor is acquiring the Interest for investment for such
Investor’s own account, and not with a view to, or for resale in connection with, any distribution thereof, and Investor has
no present intention of selling or distributing any of the Interest; (vi) Investor has had an opportunity to discuss Company’s
business, management and financial affairs with its management and to obtain any additional information which Investor has deemed
necessary or appropriate for deciding whether or not to purchase the Interest, including an opportunity to receive, review and
understand the information set forth in Company’s financial statements, capitalization and other business information as
Investor deems prudent; (vii) Investor acknowledges that no other representations or warranties, oral or written, have been made by
Company or any agent thereof except as set forth in this Agreement; (viii) Investor is aware that no federal, state or other agency
has made any finding or determination as to the fairness of the investment, nor made any recommendation or endorsement of the
Interest; (ix) Investor has such knowledge and experience in financial and business matters, including investments in other emerging
growth companies that such individual or entity is capable of evaluating the merits and risks of the investment in the Interest and
it is able to bear the economic risk of such investment, (x) Investor has such knowledge and experience in financial and business
matters that such individual or entity is capable of utilizing the information made available in connection with the offering of the
Interest, of evaluating the merits and risks of an investment in the Interest and of making an informed investment decision with
respect to the Interest; (xi) neither Investor, nor any person or entity with whom such Investor shares beneficial ownership of the
Interest, is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii); (xii)
Investor is aware that there is currently no public market for the Interest, that there is no guarantee that a public market will
develop at any time in the future and Investor understands that the Interest is unregistered and may not presently be sold except in
accordance with applicable securities laws; (xiii) Investor understands that the Interest cannot be readily sold or liquidated in
case of an emergency or other financial need; (xiv) Investor acknowledges and agrees that the Interest must be held indefinitely
unless it is subsequently registered under the 1933 Act or an exemption from such registration is available, and Investor has been
advised or is aware of the provisions of Rule 144 promulgated under the 1933 Act as in effect from time to time, which permits
limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions, including, among
other things: the availability of certain current public information about the Company and the resale occurring following the
required holding period under Rule 144; and (xv) each instrument evidencing the Interest which Investor may purchase hereunder may
be imprinted with legends substantially in the following form:

 

“THIS INTEREST
HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES
IN THE UNITED STATES. THIS INTEREST IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT
AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.”

 

Notwithstanding the foregoing
representations and warranties, Company acknowledges and agrees that such representations and warranties do not affect Company’s
obligations to repay the Interest in full pursuant to the terms thereof.

 

    2 

     

    

 

3.                   Company’s
Representations and Warranties. Company represents and warrants to Investor that as of the Closing Date: (i) Company is a
corporation duly organized, validly existing and in good standing under the laws of its state of incorporation and has the requisite
corporate power to own its properties and to carry on its business as now being conducted; (ii) Company is duly qualified as a
foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so qualified would not reasonably be
expected to have a material adverse effect on Borrower’s business, assets, properties, operations or financial condition or
its ability to perform its obligations hereunder (a “Material Adverse Effect”); (iii) Company has registered its
Common Stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), and is
obligated to file reports pursuant to Section 13 or Section 15(d) of the 1934 Act; (iv) each of the Transaction Documents
and the transactions contemplated hereby and thereby, have been duly and validly authorized by Company and all necessary actions
have been taken; (v) this Agreement, the Interest, and the other Transaction Documents have been duly executed and delivered by
Company and constitute the valid and binding obligations of Company enforceable in accordance with their terms, except as
enforceability may be limited by applicable bankruptcy, insolvency and similar laws affecting creditors’ rights and by general
principles of equity; (vi) the execution and delivery of the Transaction Documents by Company, the issuance of the Interest in
accordance with the terms hereof, and the consummation by Company of the other transactions contemplated by the Transaction
Documents do not and will not conflict with or result in a breach by Company of any of the terms or provisions of, or constitute a
default under (a) Company’s formation documents or bylaws, each as currently in effect, (b) any indenture, mortgage, deed of
trust, or other material agreement or instrument to which Company is a party or by which it or any of its properties or assets are
bound, including, without limitation, any listing agreement for the Common Stock, except as would not reasonably be expected to have
a Material Adverse Effect, or (c) any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of
any court, United States federal, state or foreign regulatory body, administrative agency, or other governmental body having
jurisdiction over Company or any of Company’s properties or assets, except as would not reasonably be expected to have a
Material Adverse Effect; (vii) no further authorization, approval or consent of any court, governmental body, regulatory agency,
self-regulatory organization, or stock exchange or market or the stockholders or any lender of Company is required to be obtained by
Company for the issuance of the Interest to Investor or the entering into of the Transaction Documents; (viii) none of
Company’s filings with the SEC contained, at the time they were filed, any untrue statement of a material fact or omitted to
state any material fact required to be stated therein or necessary to make the statements made therein, in light of the
circumstances under which they were made, not materially misleading; (ix) within the 12 months immediately preceding the date
hereof, Company has filed all reports, schedules, forms, statements and other documents required to be filed by Company with the SEC
under the 1934 Act on a timely basis or has received a valid extension of such time of filing and has filed any such report,
schedule, form, statement or other document prior to the expiration of any such extension; (x) there is no action, suit, proceeding,
inquiry or investigation before or by any court, public board or body pending or, to the knowledge of Company, threatened against or
affecting Company before or by any governmental authority or non-governmental department, commission, board, bureau, agency or
instrumentality or any other person which would reasonably be expected to have a Material Adverse Effect; (xi) Company has not
consummated any financing transaction that has not been disclosed in a periodic filing or current report with the SEC under the 1934
Act; (xii) Company is not, nor has it been at any time in the previous twelve (12) months, a “Shell Company,” as such
type of “issuer” is described in Rule 144(i)(1) under the 1933 Act; (xiii) with respect to any commissions, placement
agent or finder’s fees or similar payments that will or would become due and owing by Company to any person or entity as a
result of this Agreement or the transactions contemplated hereby (“Broker Fees”), any such Broker Fees will be
made in full compliance with all applicable laws and regulations and only to a person or entity that is a registered investment
adviser or registered broker-dealer; (xiv) Investor shall have no obligation with respect to any Broker Fees or with respect to any
claims made by or on behalf of other persons for fees of a type contemplated in this subsection that may be due in connection with
the transactions contemplated hereby and Company shall indemnify and hold harmless each of Investor, Investor’s employees,
officers, directors, stockholders, members, managers, agents, and partners, and their respective affiliates, from and against all
claims, losses, damages, costs (including the costs of preparation and attorneys’ fees) and expenses suffered in respect of
any such claimed Broker Fees; (xv) neither Investor nor any of its officers, directors, stockholders, members, managers, employees,
agents or representatives has made any representations or warranties to Company or any of its officers, directors, employees, agents
or representatives except as expressly set forth in the Transaction Documents and, in making its decision to enter into the
transactions contemplated by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise
of Investor or its officers, directors, members, managers, employees, agents or representatives other than as set forth in the
Transaction Documents; (xvi) Company acknowledges that the State of Utah has a reasonable relationship and sufficient contacts to
the transactions contemplated by the Transaction Documents and any dispute that may arise related thereto such that the laws and
venue of the State of Utah, as set forth more specifically in Section 8.3 below, shall be applicable to the Transaction Documents
and the transactions contemplated therein; (xvii) Company acknowledges that Investor is not registered as a ‘dealer’
under the 1934 Act; and (xviii) Company has performed due diligence and background research on Investor and its affiliates and has
received and reviewed the due diligence packet provided by Investor. Company, being aware of the matters and legal issues described
in subsections (xvii) and (xviii) above, acknowledges and agrees that such matters, or any similar matters, have no bearing on the
transactions contemplated by the Transaction Documents and covenants and agrees it will not use any such information or legal theory
as a defense to performance of its obligations under the Transaction Documents or in any attempt to avoid, modify, reduce, rescind
or void such obligations.

 

    3 

     

    

 

4.                  
Company Covenants. Until all of Company’s obligations (other than contingent and indemnification obligations) under
all of the Transaction Documents are paid in full, or within the timeframes otherwise specifically set forth below, Company will at all
times comply with the following covenants: (i) so long as the Interest is outstanding and for at least twenty (20) Business Days (as defined
in the Interest) thereafter, Company will timely file on the applicable deadline (including any extensions thereof) all reports required
to be filed with the SEC pursuant to Sections 13 or 15(d) of the 1934 Act that would otherwise impact the availability of Rule 144
of the 1933 Act, and will take all reasonable action under its control to ensure that adequate current public information with respect
to Company, as required in accordance with Rule 144 of the 1933 Act, is publicly available, and until a Fundamental Transaction (as defined
in the Interest) will not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules
and regulations thereunder would permit such termination; (ii) until a Fundamental Transaction, the Common Stock shall be listed or quoted
for trading on any of (a) NYSE, (b) NASDAQ, (c) OTCQX, or (d) OTCQB; (iii) until a Fundamental Transaction, trading in Company’s
Common Stock will not be suspended, halted, chilled, frozen, reach zero bid or otherwise cease on Company’s principal trading market;
(iv) unless an acquiring party specifically agrees to assume all rights and obligations associated with the Interest and, in Investor’s
discretion is capable of fulfilling such obligations, Company may not consummate any sale or liquidation of all or substantially all of
its business or any material asset outside the ordinary course of business without the prior written consent of Investor; (v) Company
will not grant a security or royalty interest in any of the Included Products (as defined in the Interest) for the primary purpose of
raising capital without Investor’s prior written consent, which for the avoidance of doubt, shall exclude any of the Included Products
with one or more business development partners in connection with a licensing transaction or collaboration; and (vi) for so long as the
Interest remains outstanding, Company shall deliver to Investor quarterly reports summarizing all Included Products revenues and Net Sales
(as defined in the Interest) and shall further hold with Investor a quarterly call with Company’s management to discuss such report,
provided that Company will not disclose any material non-public information to Investor without Investor’s prior written consent.

 

5.                  
Conditions to Company’s Obligation to Sell. The obligation of Company hereunder to sell the Interest to Investor at
the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following conditions:

 

5.1.             
Investor shall have executed this Agreement and delivered the same to Company.

 

5.2.            
  Investor shall have delivered the Purchase Price to Company in accordance with Section 1.2 above.

 

6.                  
 Conditions to Investor’s Obligation to Purchase. The obligation of Investor hereunder to purchase the Interest at
the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following conditions, provided that these conditions
are for Investor’s sole benefit and may be waived by Investor at any time in its sole discretion:

 

6.1.             
Company shall have executed this Agreement and the Interest and delivered the same to Investor.

 

6.2.              Company shall have delivered to Investor a fully executed Secretary’s Certificate substantially in the form attached hereto
as Exhibit B evidencing Company’s approval of the Transaction Documents.

 

6.3.              Company shall have delivered to Investor fully executed copies of all Transaction Documents required to be executed by Company
herein or therein.

 

7.                  
Audit Right. Company shall keep and maintain current, complete and accurate books and records as are necessary and material
to determine its compliance with its payment obligations under the Interest. Such books and records shall be kept and maintained in accordance
with generally accepted accounting principles consistently applied. Investor or its authorized representative shall have the right to
retain an independent certified public accountant of its choosing to audit the books and records of Company, at Investor’s expense,
to determine whether Company is in compliance with its payment obligations under the Interest. If an audit reveals that Investor has been
underpaid, Company shall immediately pay Investor such underpaid amount plus interest thereon at the rate of 18% per annum, compounding
daily, or, if lower, the highest rate allowed by law. If such underpayment exceeds 1% of the amount due, then, without prejudice to Investor’s
other rights and remedies, Company shall also pay for the cost of the audit. If the audit reveals that Investor has been overpaid, Investor
authorizes Company to offset such overpayment against future royalties. The auditor shall be required to agree to keep confidential all
confidential information of Company learned during the course of the audit, except as necessary to report to Investor. Moreover, and notwithstanding
the foregoing, Company shall not disclose any material non-public information to Investor without Investor’s prior written consent.
Any such audit shall be performed only during Company’s normal business hours upon reasonable prior notice, no more frequently than
once per calendar quarter, and shall be performed in such a manner as to avoid unreasonable interference with Company’s business
operations.

 

    4 

     

    

 

8.                  
Miscellaneous. The provisions set forth in this Section 8 shall apply to this Agreement, as well as all other Transaction
Documents as if these terms were fully set forth therein; provided, however, that in the event there is a conflict between any
provision set forth in this Section 8 and any provision in any other Transaction Document, the provision in such other Transaction Document
shall govern.

 

8.1.            
Certain Capitalized Terms. To the extent any capitalized term used in any Transaction Document is defined in any other Transaction
Document (as noted therein), such capitalized term shall remain applicable in the Transaction Document in which it is so used even if
the other Transaction Document (wherein such term is defined) has been released, satisfied, or is otherwise cancelled or terminated.

 

8.2.             Arbitration
of Claims. The parties shall submit all claims, disputes and causes of action (each, a “Claim”) arising under
this Agreement or any other Transaction Document or any other agreement between the parties and their affiliates or any Claim
relating to the relationship of the parties to binding arbitration pursuant to rules of the American Arbitration Association. Within
seven (7) calendar days of initiation of arbitration by either party, Investor will provide a list of five (5) arbitrators that are
designated as “neutrals” or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such five (5)
arbitrators, the “Proposed Arbitrators”). Within five (5) calendar days after Investor has submitted to Company
the names of the Proposed Arbitrators, Company must select by written notice to Investor, one (1) of the Proposed Arbitrators to act
as the arbitrator. If Company fails to select one of the Proposed Arbitrators in writing within such 5-day period, then Investor may
select the arbitrator from the Proposed Arbitrators by providing written notice of such selection to Company. The arbitrator shall
be instructed to complete and shall complete the arbitration within six (6) months of commencement and shall only allow limited
discovery on issues directly related to the applicable Claims. The parties hereby acknowledge and agree that the arbitration
provisions set forth in this Section 8.2 (the “Arbitration Provisions”) are unconditionally binding on the
parties hereto and are severable from all other provisions of this Agreement. By executing this Agreement, Company represents,
warrants and covenants that Company has reviewed the Arbitration Provisions carefully, consulted with legal counsel about such
provisions (or waived its right to do so), understands that the Arbitration Provisions are intended to allow for the expeditious and
efficient resolution of any dispute hereunder, agrees to the terms and limitations set forth in the Arbitration Provisions, and that
Company will not take a position contrary to the foregoing representations. Company acknowledges and agrees that Investor may rely
upon the foregoing representations and covenants of Company regarding the Arbitration Provisions.

 

8.3.            
Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the
construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State of Utah,
without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the State of Utah. Each party consents to and expressly agrees
that the exclusive venue for arbitration of any dispute arising out of or relating to any Transaction Document or the relationship of
the parties or their affiliates shall be in Salt Lake County, Utah. Without modifying the parties obligations to resolve disputes hereunder
pursuant to the Arbitration Provisions, for any litigation arising in connection with any of the Transaction Documents, each party hereto
hereby (i) consents to and expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in Salt Lake
County, Utah, (ii) expressly submits to the exclusive venue of any such court for the purposes hereof, (iii) agrees to not bring any such
action outside of any state or federal court sitting in Salt Lake County, Utah, and (iv) waives any claim of improper venue and any claim
or objection that such courts are an inconvenient forum or any other claim, defense or objection to the bringing of any such proceeding
in such jurisdiction or to any claim that such venue of the suit, action or proceeding is improper. Finally, Company covenants and agrees
to name Investor as a party in interest in, and provide written notice to Investor in accordance with Section 8.12 below prior to bringing
or filing, any action (including without limitation any filing or action against any person or entity that is not a party to this Agreement)
that is related in any way to the Transaction Documents or any transaction contemplated herein or therein, and further agrees to timely
name Investor as a party to any such action. Company acknowledges that the governing law and venue provisions set forth in this Section
8.3 are material terms to induce Investor to enter into the Transaction Documents and that but for Company’s agreements set forth
in this Section 8.3 Investor would not have entered into the Transaction Documents.

 

8.4.             Specific
Performance. Company acknowledges and agrees that irreparable damage may occur to Investor in the event that Company fails to
perform any material provision of this Agreement or any of the other Transaction Documents in accordance with its specific terms. It
is accordingly agreed that Investor shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions
of this Agreement or such other Transaction Document and to enforce specifically the terms and provisions hereof or thereof, this
being in addition to any other remedy to which the Investor may be entitled under the Transaction Documents, at law or in equity.
For the avoidance of doubt, in the event Investor seeks to obtain an injunction against Company or specific performance of any
provision of any Transaction Document, such action shall not be a waiver of any right of Investor under any Transaction Document, at
law, or in equity, including without limitation its rights to arbitrate any Claim pursuant to the terms of the Transaction
Documents.

 

    5 

     

    

 

8.5.            
Counterparts. Each Transaction Document may be executed in any number of counterparts, each of which shall be deemed an
original, but all of which together shall constitute one instrument. The parties hereto confirm that any electronic copy of another party’s
executed counterpart of a Transaction Document (or such party’s signature page thereof) will be deemed to be an executed original
thereof.

 

8.6.            
Document Imaging. Investor shall be entitled, in its sole discretion, to image or make copies of all or any selection of
the agreements, instruments, documents, and items and records governing, arising from or relating to any of Company’s loans, including,
without limitation, this Agreement and the other Transaction Documents, and Investor may destroy or archive the paper originals. The
parties hereto (i) waive any right to insist or require that Investor produce paper originals, (ii) agree that such images shall be accorded
the same force and effect as the paper originals, (iii) agree that Investor is entitled to use such images in lieu of destroyed or archived
originals for any purpose, including as admissible evidence in any demand, presentment or other proceedings, and (iv) further agree that
any executed facsimile (faxed), scanned, emailed, or other imaged copy of this Agreement or any other Transaction Document shall be deemed
to be of the same force and effect as the original manually executed document.

 

8.7.            
Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the
interpretation of, this Agreement.

 

8.8.            
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified
to conform to such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

8.9.            
Entire Agreement. This Agreement, together with the other Transaction Documents, contains the entire understanding of the
parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Company
nor Investor makes any representation, warranty, covenant or undertaking with respect to such matters. For the avoidance of doubt, all
prior term sheets or other documents between Company and Investor, or any affiliate thereof, related to the transactions contemplated
by the Transaction Documents (collectively, “Prior Agreements”), that may have been entered into between Company and
Investor, or any affiliate thereof, are hereby null and void and deemed to be replaced in their entirety by the Transaction Documents.
To the extent there is a conflict between any term set forth in any Prior Agreement and the term(s) of the Transaction Documents, the
Transaction Documents shall govern.

 

8.10.         
No Reliance. Company acknowledges and agrees that neither Investor nor any of its officers, directors, members, managers,
representatives or agents has made any representations or warranties to Company or any of its officers, directors, representatives, agents
or employees except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions contemplated
by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise of Investor or its officers,
directors, members, managers, agents or representatives other than as set forth in the Transaction Documents.

 

8.11.         
Amendments. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by both
parties hereto.

 

    6 

     

    

 

8.12.         
 Notices. Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall
be deemed effectively given on the earliest of: (i) the date delivered, if delivered by personal delivery as against written receipt therefor
or by email to an executive officer, or by facsimile (with successful transmission confirmation), (ii) the earlier of the date delivered
or the third Business Day after deposit, postage prepaid, in the United States Postal Service by certified mail, or (iii) the earlier
of the date delivered or the third Business Day after mailing by express courier, with delivery costs and fees prepaid, in each case,
addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate
by five (5) calendar days’ advance written notice similarly given to each of the other parties hereto):

 

If to Company:

 

Jaguar Health, Inc.

Attn: Lisa A. Conte

200 Pine Street, Suite 400

San Francisco, CA 94105

 

With a copy to (which copy shall not constitute notice):

 

Reed Smith LLP

Attn: Don Reinke

101 Second Street, Suite 1800

San Francisco, CA 94105-3659

 

If to Investor:

 

Streeterville Capital, LLC

Attn: John Fife

303 East Wacker Drive, Suite 1040

Chicago, Illinois 60601

 

With a copy to (which copy shall not constitute notice):

 

Hansen Black Anderson Ashcraft PLLC

Attn: Jonathan Hansen

3051 West Maple Loop Drive, Suite 325

Lehi, Utah 84043

 

8.13.         
Successors and Assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be
performed by Investor hereunder may be assigned by Investor to a third party, including its affiliates, in whole or in part, without the
need to obtain Company’s consent thereto. Company may not assign its rights or obligations under this Agreement or delegate its
duties hereunder without the prior written consent of Investor.

 

8.14.         
Survival. The representations and warranties of Company and the agreements and covenants set forth in this Agreement shall
survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of Investor. Company agrees to
indemnify and hold harmless Investor and all its officers, directors, employees, attorneys, and agents for loss or damage arising as a
result of or related to any breach or alleged breach by Company of any of its representations, warranties and covenants set forth in this
Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

    7 

     

    

 

8.15.         
 Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

8.16.         
Investor’s Rights and Remedies Cumulative; Liquidated Damages. All rights, remedies, and powers conferred in this
Agreement and the Transaction Documents are cumulative and not exclusive of any other rights or remedies, and shall be in addition to
every other right, power, and remedy that Investor may have, whether specifically granted in this Agreement or any other Transaction Document,
or existing at law, in equity, or by statute, and any and all such rights and remedies may be exercised from time to time and as often
and in such order as Investor may deem expedient. The parties acknowledge and agree that upon Company’s failure to comply with the
provisions of the Transaction Documents, Investor’s damages would be uncertain and difficult (if not impossible) to accurately estimate
because of the parties’ inability to predict future interest rates and future share prices, Investor’s increased risk, and
the uncertainty of the availability of a suitable substitute investment opportunity for Investor, among other reasons. Accordingly, any
fees, charges, and default interest due under the Interest and the other Transaction Documents are intended by the parties to be, and
shall be deemed, liquidated damages (under Company’s and Investor’s expectations that any such liquidated damages will tack
back to the Closing Date for purposes of determining the holding period under Rule 144 under the 1933 Act). The parties agree that such
liquidated damages are a reasonable estimate of Investor’s actual damages and not a penalty, and shall not be deemed in any way
to limit any other right or remedy Investor may have hereunder, at law or in equity. The parties acknowledge and agree that under the
circumstances existing at the time this Agreement is entered into, such liquidated damages are fair and reasonable and are not penalties.
All fees, charges, and default interest provided for in the Transaction Documents are agreed to by the parties to be based upon the obligations
and the risks assumed by the parties as of the Closing Date and are consistent with investments of this type. The liquidated damages provisions
of the Transaction Documents shall not limit or preclude a party from pursuing any other remedy available at law or in equity; provided,
however, that the liquidated damages provided for in the Transaction Documents are intended to be in lieu of actual damages.

 

8.17.         
Attorneys’ Fees and Cost of Collection. In the event of any arbitration or action at law or in equity to enforce or
interpret the terms of this Agreement or any of the other Transaction Documents, the parties agree that the party who is awarded the most
money (which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges
awarded to any party) shall be deemed the prevailing party for all purposes and shall therefore be entitled to an additional award of
the full amount of the reasonable and documented out-of-pocket attorneys’ fees, deposition costs, and expenses paid by such prevailing
party in connection with arbitration or litigation without reduction or apportionment based upon the individual claims or defenses giving
rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrator’s or a court’s power to award fees and
expenses for frivolous or bad faith pleading. If (i) the Interest is placed in the hands of an attorney for collection or enforcement
prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Investor
otherwise takes action to collect amounts due under the Interest or to enforce the provisions of the Interest, or (ii) there occurs
any bankruptcy, reorganization, receivership of Company or other proceedings affecting Company’s creditors’ rights and involving
a claim under the Interest; then Company shall pay the costs incurred by Investor for such collection, enforcement or action or in connection
with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees, expenses,
deposition costs, and disbursements.

 

    8 

     

    

 

8.18.          Waiver.
No waiver of any provision of this Agreement shall be effective unless it is in the form of a writing signed by the party granting
the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or
consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent
or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.

 

8.19.         
Waiver of Jury Trial. EACH PARTY TO THIS AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH
PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, ANY OTHER
TRANSACTION DOCUMENT, OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND
A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT
SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY’S RIGHT TO DEMAND TRIAL BY JURY.

 

8.20.         
Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of this Agreement
and the other Transaction Documents.

 

8.21.         
Voluntary Agreement. Company has carefully read this Agreement and each of the other Transaction Documents and has asked
any questions needed for Company to understand the terms, consequences and binding effect of this Agreement and each of the other Transaction
Documents and fully understand them. Company has had the opportunity to seek the advice of an attorney of Company’s choosing, or
has waived the right to do so, and is executing this Agreement and each of the other Transaction Documents voluntarily and without any
duress or undue influence by Investor or anyone else.

 

[Remainder of page intentionally left blank;
signature page follows]

 

    9 

     

    

 

IN WITNESS WHEREOF, the undersigned
Investor and Company have caused this Agreement to be duly executed as of the date first above written.

 

 

	 	INVESTOR:
	 	 
	 	STREETERVILLE CAPITAL,
    LLC 
	 	 	 
	 	By:	/s/ John M. Fife
	 	 	John M. Fife, President

 

	 	COMPANY:  
	 	 
	 	JAGUAR HEALTH, INC.
    
	 	 	 
	 	By:	/s/ Lisa Conte
	 	 	Lisa Conte, President and CEO

 

[Signature Page to Royalty Interest Purchase Agreement]

 

    

     

    

 

ATTACHED EXHIBITS:

 

		Exhibit A	Interest

		Exhibit B	Secretary’s CertificateExhibit
10.1

 

“Pursuant
to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because
it is both (i) not material and (ii) the type that the registrant treats as private or confidential.”

 

合同编号No.:

 

Contract No.:

 

委托加工合同

 

Entrusted Processing Contract

 

甲方(委
托 方):

    

 

 

Party A (Client): Gelteq Pty Ltd
(ACN: 619 501 254)

 

乙方(被委托方):
蜡笔小新(福建)食品工业有限公司

 

 

Party B (Entrusted Party): 

 

依据《中华人民共和国民法典》等相关法律、法规之规定,甲、乙双方本着互惠互利长期合作的原则,在平等自愿的基础上,经协商一致,就甲方委托乙方生产加工指定系列产品的相关事宜制定并签署本合同。本合同明确了双方的义务、责任和权利,以资双方共同遵守。

 

In accordance with the Civil Code of the People’s
Republic of China and other relevant laws and regulations, Party A and Party B, on the basis of equality and voluntariness, have made
and signed this contract with mutual benefit and long-term cooperation. This contract defines the obligations, responsibilities and rights
of both parties in order to be abided by.

 

第一节 合作关系概述

 

Section I Overview of Cooperation Relationship

 

第一条 甲方授权乙方在生产加工及包装制作中使用甲方所有的
等商标。

 

Article 1. Party A authorizes Party B to use
the trademarks owned by Party A solely for the production, processing and packaging of Party A’s products pursuant to this Agreement.

 

第二条 乙方承担本合同约定的加工制作任务,并保证所加工产品的生产、质量等符合相关规定。

 

Article
2. Party B shall undertake the processing and manufacturing tasks stipulated in this contract, and ensure that the production and quality
of the processed products meet relevant regulations.

 

     

     

    

 

第二节 加工品项及原料供应

 

Section II Processing items and
Raw Material Supply

 

第一条 甲方委托乙方加工生产的产品品项是:
附件一 《代工产品信息表》

 

Article 1. The products entrusted by Party A
to Party B for processing and production are: Annex I “Information Sheet of Substitute Products”

 

第二条
甲方委托乙方加工产品所需的全部物料(原辅料、食品添加剂、包装膜(袋)、纸箱、隔板、产品合格证、封箱胶纸等)由乙方根据甲方产品需求采购提供。甲方对乙方供应商的选择原则上不干预,但乙方必须保证对供应商资质及所供产品进行严格审核,相应资料须留档备查,配方一经确认,供应商未经乙方许可不可随意变更。物料由乙方自行负责仓库存放管理、库存与采购计划管理等,甲方不承担任何由物料原因引起的相关责任。

 

Article 2. Party A engage Party B to purchase
and provide all materials (raw and auxiliary materials, food additives, packaging film (bags), cartons, partitions, product certificates,
box sealing rubber paper, etc). required for processing of Party A’s products. Party A shall not interfere in the selection of Party
B’s suppliers in principle, but Party B must ensure that the qualification of the supplier and the products provided are strictly reviewed,
and the corresponding data shall be kept for reference and once the formula is confirmed, the supplier shall not change it at will without
the permission of Party B. Party B shall be responsible for the warehouse storage management of packaging and raw ingredients and components,
inventory and procurement plan management, etc. Party A shall not bear any relevant responsibilities or costs caused by the material reasons.

 

第三条
乙方提供中文配料信息,由甲方负责翻译并保证正确性;包装设计的文字宣传及标签标识的合规性由甲方负责。乙方根据甲方提供的稿件进行印刷制作。

 

Article 3. Party B shall provide ingredients information
in Chinese which must be accurate, and Party A shall be responsible for translation to English and the accuracy of the translation. Party
A shall be responsible for the text drafting and label marking compliance of packaging design. Party B shall print and make the manuscript
provided by Party A.

 

第三节 加工成品质量安全要求及质量保证

 

Section III Quality and Safety Requirements
and Quality Assurance of Finished Products

 

第一条 乙方保证生产的产品质量必须符合甲方提供的要求以及甲方质量内控标准。

 

Article 1. Party B shall ensure that the quality
of the products and packaging produced must conform to the requirements provided by Party A and Party A’s internal quality control standards.

 

第二条
乙方必须严格按照核算成本时的配方工艺、技术标准等为甲方生产产品,并对其生产加工的产品质量全面负责。严格禁止超甲方规定范围、超甲方规定限量使用食品添加剂;严格禁止将非食品原料在食品中使用。如违反本条规定,所造成的一切经济损失及法律责任由乙方负责。

 

    2

     

    

 

Article 2. Party B shall strictly follow the formula
process, specifications and technical standards when calculating the cost to produce the products for Party A, and be fully responsible
for the quality of the products produced and processed, and strictly prohibit the use of any ingredients or manufacturing process that
does not conform with Party A’s product specifications. It is strictly forbidden to use non-food using raw materials in food. In
case of violation of this article, Party B shall be responsible for all economic losses and legal liabilities caused.

 

第三条
甲方质量技术人员不参与乙方生产质量管理,生产全过程的质量管理控制均由乙方负责。如生产过程中出现质量问题的,所造成的一切经济损失及法律责任由乙方负责。

 

Article 3. Party
A’s quality and technical personnel shall not participate in Party B’s production quality management, and Party B shall be responsible
and accepts liability for the quality management control of the whole production process. Party B shall be responsible for all economic
loss and legal liabilities in the event that quality problems ocurr during or as a result of the manufacturing process.

 

第四节
产品检验

 

Section
IV Product Inspection

 

第一条 乙方对加工产品进行过程检验及出厂前检验,必须确保产品合格方能出库,乙方须提供所送每批次产品的自检报告。甲方另外有其他质量要求的,按照双方的另行约定执行。如果产品不符合本协议的要求,乙方需尽快通知甲方,并承担补救的费用,

 

Article 1. Party B shall carry out process inspection
and pre delivery inspection on all products, and ensure that the products can be delivered to Party A for the intended purpose, after
passing the inspection. Party B shall provide self inspection report of each batch of products. If Party A has other quality requirements,
it shall be implemented in accordance with the other agreement between the two parties. If the products do not conform with the requirements
of this Agreement then Party B must inform Party A as soon as possible and must remedy the issue at its cost as soon as possible.

 

第五节 产品下单及交货程序

 

Section V Order and Delivery Procedure of Products

 

第一条
甲方根据经营需要,以传真、电子邮件、或扫描件等形式将经相关责任人确定并签名的《订购单》(见附件二)发给乙方的指定联系人。乙方代表收到订购单应于2个工作日内确认产品明细及交期后,经责任人签字并回复甲方指定联系人。如果甲方接受乙方提出的交期,需签字确认并先行支付订单总金额的
70%。

 

    3

     

    

 

Article 1. Party A shall, according to the business
needs, send the Order Form (see Annex II) confirmed and signed by the relevant responsible person to the designated contact person of
Party B in the form of fax, email, or scanning copy. Party B’s representative shall confirm the product details and delivery date within
2 working days after receiving the Order Form, and then sign and reply to the designated contact person of Party A. If Party A accepts
the proposed delivery date it will then also sign the Order Form and pay 70% of the total order price.

 

第二条
任何一方要求更改订单数量或改期交货应当事先与对方达成协议,在《订购单》备注并双方确认签字。

 

Article 2. Any party requiring change of order
quantity or rescheduled delivery shall reach an agreement with the other party in advance, make remarks on the Order Form and both parties
shall confirm and both parties are to sign the revised Order Form.

 

第三条
乙方必须按甲方的订购单严格组织生产,按照双方约定的交货地点及交货方式交付货品。

 

Article 3. Party B shall strictly organize production
according to the order of Party A, and deliver the goods according to the delivery date, place and method agreed by both parties.

 

第四条
甲方收到乙方交付的货物后,应及时组织相关人员依据相关质量标准和卫生标准等文件要求对货物数量和质量进行验收,并开具入库单交由乙方。如果甲方验收不合格的,则甲方有权对不合格批次的货物退货,并要求乙方在加工合同金额限度内承担损失。

 

Article 4. After receiving the goods delivered
by Party B, Party A may organize relevant personnel to inspect the quantity and quality of goods according to relevant quality standards,
health standards and other documents, then issue the warehousing list and submit them to Party B. If the goods are found to be unqualified,
Party A shall have the right to return the unqualified goods and require Party B to bear all the losses caused to Party A limited to the
manufacturing contract amount.

 

第五条
甲乙双方如对质量判定存在异议,可在甲乙双方共同认可的第三方检验机构进行检验。

 

Article 5. If Party A does not consider that the products comply with
this Agreement then then the products can be inspected by a third-party inspection institution recognized by both parties.

 

第六条
结合生产实际情况,甲方允许乙方交付的订购产品数量存在偏差,偏差数量不超过甲方《订购单》所列总数量的
(±10% )。

 

Article 6. In combination with the actual production
conditions, Party A allows Party B to deliver the ordered products with deviation, which shall not exceed the total quantity listed in
the purchase order of Party A (± 10%).

 

第六节 包材押金,供应价格及起订量

 

    4

     

    

 

Section VI Deposit, Supply Price
and MOQ

 

第一条 押金:甲方须向乙方交纳(15)万元的版费、定制包材及专用原料的押金。乙方应在本合同终止后
(7)个工作日内返还至甲方指定账户。本押金不计任何利息。

 

Article 1. Deposit: Party A shall pay Party B
150,000RMB up front which be used for Printing Mould Cost, Customized Deposit for packaging materials and special raw materials. If there
is any unused portion of the deposit then Party B shall return it to the account designated by Party A within (7) working days after the
termination of this contract. This deposit is free of any interest.

 

第二条 订购产品的价格及产品包装规格:见附件一
《代工产品信息表》。

 

Article 2. The parties agree that the price and
packaging specifications of ordered products are as set out in Annex I ” Information Sheet of OEM Products”.

 

第三条
在合同有效期内,原则上不允许乙方调整价格,如确因原料价格变化巨大等特殊情况,乙方需对约定价格进行调整的,乙方应提前至少(30)天书面通知甲方,列明调价原因及调整幅度。甲方应于(7)个工作日内书面回复同意与否。如甲方同意调整方案,涉及的相关产品名称、包装规格、价格及新价格生效日期,需重新提报《代工产品信息表》并经双方责任人签字后方可生效,并必须作为本合同附件之一存档。如甲方不同意调整方案,乙方应严格按照原合同进行。

 

Article 3. In principle, Party B is not allowed
to adjust the price during the validity of the contract. If Party B needs to adjust the agreed price due to the special circumstances
such as the huge change of raw material price, Party B shall inform Party A in writing at least (30) days in advance, and list the reasons
and adjustment range and will only apply to Orders submitted after the date of notification. Party A shall reply in writing within (7)
working days. If Party A agrees to adjust the plan, the relevant product name, packaging specification, price and the effective date of
new price involved shall be re-submitted to Information Sheet of Substitute Products and signed by the responsible persons of both parties,
and shall be filed as one of the annexes to the contract. If Party A does not agree to adjust the plan, Party B shall perform this contract
as originally agreed.

 

第四条
双方就新价格及生效日期达成协议以前,甲、乙双方均须按照合同已经确定价格履行相关义务及责任,乙方不得以此为由单方面停止供货。如因乙方单方面违约行为造成的一切经济损失及法律责任由乙方承担。

 

Article 4. Before the parties reach an agreement
on the new price and effective date, both parties shall perform relevant obligations and responsibilities according to the price already
determined in the contract. Party B shall not unilaterally stop the supply on this basis. All economic losses and legal liabilities caused
by Party B’s unilateral breach of contract shall be borne by Party B.

 

第五条
产品起订量:单品订单须至少满足 (1000)
件。

 

Article 5. MOQ: the order of single product must
meet at least (1000) pieces.

 

第七节 货款结算

 

    5

     

    

 

Section VII Payment Settlement

 

第一条 结算方式:订单下达二日内支付订单总金额的70%,发货前付清30%余款。

 

Article 1. Settlement: 70% of the total order
amount shall be paid within two days after the order has been accepted by Party B and Party A has agreed to the proposed delivery date,
and 30% of the balance shall be paid by Party A to Party B before delivery of the order.

 

第二条 支付方式:£电汇
£现金 □支票 □银行承兑汇票 □其他

 

甲方将确保乙方收到货款的币种为人民币,甲方将负责承担将甲方支付的任何款项换汇成人民币的费用。

 

Article 2. Payment method: □ Telegraphic
transfer □ Cash □ check □ bank acceptance bill □ others

 

Party A will ensure that the currency of payment
received by Party B is RMB, and Party A will be responsible for the cost of converting any payment paid by Party A into RMB.

 

第三条 收款信息:详见附件三《蜡笔小新银行信息》

 

Article 3. Payment information: refer to Annex
III “BANK INFORMATION FROM LABIXIAOXIN”.

 

第八节 保密条款及其它

 

Section VIII Confidentiality and
Other

 

第一条 本合同的商洽、签订及履行过程中,一方从另一方获悉的相关技术资料、商业信息以及相关数据等信息均为保密资料。合同有效期内及合同终止后,双方对上述保密资料均有保密义务,法律的规定予以披露的除外。

 

Article 1. During the negotiation, signing and
performance of this contract, the relevant technical data, product specifications and formulations, commercial information and relevant
data and other information learned by one party from the other party are confidential data of Party A. During the validity period of the
contract and after the termination of the contract, Party B has the obligation to keep confidential the above confidential information,
except for the disclosure required by law. Party B must not use any of Party A’s confidential information for any purpose other
than for the fulfilment of its obligations under this Agreement unless agreed by both parties.

 

第二条
商标仅限生产甲方指定产品时使用,乙方无权将该商标用于其他非指定产品,无权将标注有该商标的指定产品对外销售或进行其他任何方式的处置。乙方同意其不会侵犯甲方的知识产权。乙方同意其不会规避甲方的保密信息,或试图制造或开发任何使用甲方知识产权的产品。

 

    6

     

    

 

Article 2. The trademark is only used when Party
A produces the designated products, Party B has no right to use the trademark for other non designated products, and Party B has no right
to sell the designated products marked with the trademark to the outside world or dispose of it in any other way. Party B agrees that
it will not infringing the Intellectual Property of Party A. Party B agrees that it will not circumvent the Confidential Information of
Party A or attempt to manufacture or develop any products which utilizes Party A’s Intellectual Property.

 

第三条
不合格的产品或取消订单的产品乙方应严格按照报废审核程序全面回收销毁,由于报废产品流失而侵害甲方权益的,一切经济损失及法律责任由乙方承担。不合格产品产生的一切费用由乙方承担,因甲方原因取消订单产生的一切费用由甲方承担。

 

Article 3. Party B shall recycle and destroy the
unqualified products or orders from cancelled orders in strict accordance with the scrap audit procedure such products must not be sold
to any other party. If Party B infringes Party A’s rights and interests due to the loss of the scrapped products, Party B shall bear all
economic losses and legal liabilities. All expenses incurred by the unqualified products shall be borne by Party B and all expenses incurred
by the cancellation of the order for reasons attributable to Party A shall be borne by Party A.

 

第九节
不可抗力

 

Section IX Force Majeure

 

第一条 甲乙双方的任何一方由于不可抗力的原因导致不能履行合同时,应及时向对方通报不能履行或不能完全履行的原由,以减轻或避免可能给对方造成的损失。双方协商一致后,允许延期履行、部分履行或者不履行合同,并根据实际情况可部分或全部免予承担违约责任。协商内容应以书面形式并双方责任人签名后作为本合同附件存档。

 

Article 1. If either party of Party A and Party
B fail to perform the contract due to force majeure, it shall timely inform the other party of the reasons for failure or complete performance,
so as to reduce or avoid the losses that may be caused to the other party. After the two parties have reached consensus, it is allowed
to delay performance, partially perform or fail to perform the contract, and may be exempted from the liability for breach of contract
in part or in whole according to the actual situation. The negotiation contents shall be in written form and signed by the responsible
persons of both parties and shall be filed as the appendix to the contract.

 

第十节 违约责任

 

Section X Liability for Breach of Contract

 

第一条 乙方不能按合同确定的交货期交货,且未提前通知甲方并经甲方同意重新确定交货日期的,按超期(7)天以上(14)天以内
,应按照该笔订单总金额的 (0.5 %) 作为违约金;超期
(14)天以上 ,应按照该笔订单总金额的(1%)作为违约金。因乙方超期交货给甲方造成的一切经济损失及法律责任由乙方承担。

 

    7

     

    

 

Article 1. If Party
B fails to deliver the goods according to the delivery date determined in the contract and Order Form, and without prior notice to Party
A and with the consent of Party A to redetermine the delivery date, liquidated damages of the total amount of the order will be imposed
on Party B according to the following rules. If the period of overdue period is between 7 and 14 days, the liquidated damages shall be
(0.5%) of the total amount of the order. If the period of overdue period is longer than 14 days the liquidated damages shall be (1%) of
the total amount of the order. Party B shall also bear all economic losses and legal liabilities caused by Party B’s overdue delivery
to Party A. 

 

第二条
在商品标明的保质期及保质条件下,乙方应对其提供的产品质量全面负责,由此产生的一切经济损失及法律责任由乙方承担。

 

Article 2. Under the warranty period and until
the use by date of the individual products, Party B shall be fully responsible for the quality of the products provided by Party B, and
all economic losses and legal liabilities arising therefrom shall be borne by Party B. The minimum use by date for the products will be
agreed between the parties on a case by case basis.

 

第三条
甲方无正当理由逾期提货的、逾期付款的,应依逾期金额按同期银行利息(利率不超过10%)计算向乙方偿付逾期付款的违约金。逾期提货、逾期付款时间超过(30)天,乙方有权拒收甲方新增订单,直到甲方付清超期货款为止,且无须承担任由此产生的任何违约责任。

 

Article 3. If Party A fails to collect goods or
pay the goods overdue without proper reasons, Party A shall pay Party B liquidated damages for overdue payment based on the overdue amount
calculated on the basis of the bank interest charged to Party B of the same period (not more than 10%). If the overdue delivery and overdue
payment time exceed (30) days, Party B shall have the right to reject the new order of Party A until Party A pays the overdue payment,
and shall not be liable for any breach of contract arising there from.

 

第十一节 合同终止、争议解决

 

Section 11 Termination of Contract and Dispute
Resolution

 

第一条 本合同期限为:自2021年8月1日至2023年7月31日。

 

Article 1. The term of this contract is from August
1, 2021 to July 31, 2024.

 

第二条
合同期满后,本合同自动终止。若任何一方欲续展合同期限,需于合同期满前一个月内向另一方提出,协商一致后重新签署合同。

 

Article 2. After the expiration of the contract,
the contract shall continue on a month to month basis until the parties enter into a new agreement.

 

第三条
合同有效期及合同续约期内,如发生以下事项,一方有权以书面形式通知对方解除合同。

 

Article 3. During the validity and renewal of
the contract, if the following events occur, one party shall have the right to terminate the contract by written notice to the other party.

 

第一款
另一方违反保密条款或存在其他严重违约情况。

 

    8

     

    

 

Section 1. The
other party violates the confidentiality clause or has other serious breach of contract.

 

第二款
另一方进入破产清算或被兼并程序,或另一方因财务或经营情况恶化丧失履行本合同的能力。

 

Section 2. The other
party enters into bankruptcy liquidation or merger procedure, or the other party loses the ability to perform the contract due to deterioration
of financial or business conditions.

 

第三款
双方本着友好协商的原则解决因本合同的解释或履行发生的任何争议。协商不成的,
双方同意在友好谈判失败后30天内由双方商定的调解员进行正式调解。如果调解失败,双方同意将此事提交双方同意的中国法院或起诉方所在地法院。

 

Section 3. In order for the parties to resolve
any dispute arising from the interpretation or performance of this contract, it shall be settled by both parties on the principle of friendly
negotiation. If the negotiation fails, the parties agree to conduct formal mediation by a mutually agreed mediator within 30 days of the
failure of amicable negotiations. If mediation fails, the parties agree to refer the matter to a mutually agreed court in China or the
court at the location of the prosecutor.

 

第四款
本合同未尽事宜由双方协商解决,并另行签订补充协议。本合同、本合同附件、本合同补充协议以及以本合同为基础所达成的任何书面协议、共识,均为本合同的有效组成部分,与本合同有着同等法律效力。本合同的修改应以书面形式做出并由双方确认。

 

Section 4. The matters not covered in this contract
shall be settled by both parties through negotiation and a supplementary agreement shall be signed separately. This contract, the appendix
to the contract, the supplementary agreement of this contract and any written agreement and consensus reached on the basis of this contract
are all valid components of the contract and have the same legal effect as this contract. The modification of this contract shall be made
in writing and confirmed by both parties.

 

第四条 本协议以中英文订立。两种语言文本间如有歧义,以中文文本为准。

 

Article 4. This agreement is made in Chinese and
English. In case of any ambiguity between the two languages, the Chinese version shall prevail.

 

第十二节 其他

 

Section XII Others

 

第一条 如一方营业执照、地址、电话、传真号码、账户信息、开票信息、责任人,联系人等有变更,应在变更当日内书面通知对方,被通知方应当及时修改并保存变更信息。

 

Article 1. if a party has any change in its
business license, address, telephone, fax number, account information, billing information, responsible person, contact person, etc.,
it shall notify the other party in writing within the day of change, and the notified party shall modify and keep the change information
in time.

 

    9

     

    

 

第二条 本合同执行期间,双方不得随意变更或解除合同。

 

Article 2. During the execution of this contract,
both parties shall not arbitrarily change or terminate the contract.

 

第三条 本合同一式四份,经双方签字盖章后生效,甲乙双方执二份。

 

Article 3. This contract is made in quadruplicate,
and shall come into force after being signed and sealed by both parties, and both parties shall hold two.

 

(以下无正文)

 

(No text below)
 

    10

     

    

 

(本页为签字页)

 

(Signed at this page)

 

	甲 方(章): 	/S/ Nathan Givoni	 
	 	 	 
	法 定代表:	________________	 
	 	 	 
	地 址:	___________________     _______	 
	 	 	 
	委 托代表:	___________	 
	 	 	 
	联 系电话:	___	 

 

Party A (Seal): Gelteq Pty Ltd
(ACN: 619 501 254)

 

Legal Representative: Nathan Givoni

 

Address: Level 7, 616 St Kilda Rd, Melbourne
VIC 3004 Australia

 

Entrusted Representative: Nathan Givoni

 

Contact Number: +61
3 9087 3990

 

_________________________

 

乙方(章):  蜡笔小新(福建)食品工业有限公司

 

法定代表:郑育双 ______________________

 

地 址:晋江市五里工业园区
__________________________________

 

委托代表:邓伦理 _______________________

 

联系电话:0595-
85739999 __________

 

Party B (Seal): /S/Labixiaoxin (Fujian)
Foods Industrial Co.,Ltd

 

Legal Representative:

 

Address: 

 

Entrusted Representative: 

 

Tel: 

 

    11

     

    

 

 

Annex III BANK INFORMATION FROM LABIXIAOXIN

 

[*****]

 

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]